The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
androgen receptor
diagnosis
prognosis
therapy
tumor biology
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
05
10
2023
accepted:
09
10
2023
medline:
2
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
aheadofprint
Résumé
The 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 27 to 29, 2022, at the Omni La Costa Resort in Carlsbad, CA. This was the first-ever hybrid PCF Retreat. The Annual PCF Scientific Retreat is a prominent international scientific gathering centered on groundbreaking, unpublished, and influential studies in basic, translational, and clinical prostate cancer research. It also covers research from related fields with a strong potential for influencing prostate cancer research and patient care. Key areas of research that were focused on at the 2022 PCF Retreat included: (i) the contributions of molecular and genomic factors to prostate cancer disparities; (ii) novel clinical trial updates; (iii) lessons from primary prostate cancer; (iv) lessons from single-cell studies; (v) genetic, epigenetic, epitranscriptomic and posttranslational mechanisms and clinical heterogeneity in prostate cancer; (vi) biology of neuroendocrine and lineage-plastic prostate cancer; (vii) next generation prostate cancer theranostics and combination therapies; (viii) the biology and therapeutic potential of targeting phosphoinositide 3-kinases pathways; (ix) combining immunomodulatory treatments for prostate cancer; (x) novel gamma delta (γδ) T-cell therapy platforms for oncology; and (xi) lessons from other cancers. This article provides a summary of the presentations from the 2022 PCF Scientific Retreat. By disseminating this knowledge, we hope to enhance our understanding of the present research landscape and guide future strides in both prostate cancer research and patient care.
Sections du résumé
BACKGROUND
BACKGROUND
The 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 27 to 29, 2022, at the Omni La Costa Resort in Carlsbad, CA. This was the first-ever hybrid PCF Retreat.
METHODS
METHODS
The Annual PCF Scientific Retreat is a prominent international scientific gathering centered on groundbreaking, unpublished, and influential studies in basic, translational, and clinical prostate cancer research. It also covers research from related fields with a strong potential for influencing prostate cancer research and patient care.
RESULTS
RESULTS
Key areas of research that were focused on at the 2022 PCF Retreat included: (i) the contributions of molecular and genomic factors to prostate cancer disparities; (ii) novel clinical trial updates; (iii) lessons from primary prostate cancer; (iv) lessons from single-cell studies; (v) genetic, epigenetic, epitranscriptomic and posttranslational mechanisms and clinical heterogeneity in prostate cancer; (vi) biology of neuroendocrine and lineage-plastic prostate cancer; (vii) next generation prostate cancer theranostics and combination therapies; (viii) the biology and therapeutic potential of targeting phosphoinositide 3-kinases pathways; (ix) combining immunomodulatory treatments for prostate cancer; (x) novel gamma delta (γδ) T-cell therapy platforms for oncology; and (xi) lessons from other cancers.
CONCLUSIONS
CONCLUSIONS
This article provides a summary of the presentations from the 2022 PCF Scientific Retreat. By disseminating this knowledge, we hope to enhance our understanding of the present research landscape and guide future strides in both prostate cancer research and patient care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24640Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
Wallace TA, Prueitt RL, Yi M, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008;68(3):927-936.
Powell IJ, Dyson G, Land S, et al. Genes associated with prostate cancer are differentially expressed in African American and european American men. Cancer Epidemiol Biomarkers Prevent. 2013;22(5):891-897.
Yuan J, Kensler KH, Hu Z, et al. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. PLoS Genet. 2020;16(2):e1008641.
Huang FW, Mosquera JM, Garofalo A, et al. Exome sequencing of African-American prostate cancer reveals Loss-of-Function ERF mutations. Cancer Discovery. 2017;7(9):973-983.
Khani F, Mosquera JM, Park K, et al. Evidence for molecular differences in prostate cancer between African American and caucasian men. Clin Cancer Res. 2014;20(18):4925-4934.
Magi-Galluzzi C, Tsusuki T, Elson P, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, African-American and Japanese patients. Prostate. 2011;71(5):489-497.
Tosoian JJ, Almutairi F, Morais CL, et al. Prevalence and prognostic significance of PTEN loss in African-American and European-American men undergoing radical prostatectomy. Eur Urol. 2017;71(5):697-700.
Vidotto T, Imada EL, Faisal F, et al. Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer. JCI Insight. 2023;8:3.
Wang BD, Ceniccola K, Hwang S, et al. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nat Commun. 2017;8:15921.
Al Abo M, Hyslop T, Qin X, et al. Differential alternative RNA splicing and transcription events between tumors from African American and White patients in the cancer genome Atlas. Genomics. 2021;113(3):1234-1246.
Freedman JA, Al Abo M, Allen TA, Piwarski SA, Wegermann K, Patierno SR. Biological aspects of cancer health disparities. Annu Rev Med. 2021;72:229-241.
Robinson TJ, Freedman JA, Al Abo M, et al. Alternative RNA splicing as a potential major source of untapped molecular targets in precision oncology and cancer disparities. Clin Cancer Res. 2019;25(10):2963-2968.
Cheng Q, Butler W, Zhou Y, et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022;81(5):446-455.
McKay RR, Berchuck J, Kwak L, et al. Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: results of a pooled analysis of contemporary clinical trials. J Urol. 2021;205(6):1689-1697.
Ravi P, Kwak L, Xie W, et al. Neoadjuvant novel hormonal therapy followed by prostatectomy versus Up-Front prostatectomy for high-risk prostate cancer: a comparative analysis. J Urol. 2022;208(4):838-845.
Tewari AK, Cheung ATM, Crowdis J, et al. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Rep. 2021;36(10):109665.
Berchuck JE, Zhang Z, Silver R, et al. Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer. Eur Urol. 2021;80(3):295-303.
McKay RR, Ye H, Xie W, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol. 2019;37(11):923-931.
Erak E, Oliveira LD, Mendes AA, et al. Predicting prostate cancer molecular subtype with deep learning on histopathologic images. Mod Pathol. 2023;36:100247.
Lozano R, Salles DC, Sandhu S, et al. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur J Cancer. 2021;147:74-83.
Shen Y-C, Ghasemzadeh A, Kochel CM, et al. Combining intratumoral treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model. Prostate Cancer Prostatic Dis. 2018;21(1):113-125.
Hawley JE, Obradovic AZ, Dallos MC, et al. Single-cell RNAseq analysis reveals robust, anti-PD-1-mediated increase of immune infiltrate in metastatic castration-sensitive prostate cancer. bioRxiv. 2022.
Alvarez MJ, Shen Y, Giorgi FM, et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nature Genet. 2016;48(8):838-847.
Guan X, Polesso F, Wang C, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606:791-796.
Brennen WN, Zhu Y, Coleman IM, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight. 2021;6(8):e146827.
Nyquist MD, Corella A, Coleman I, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020;31(8):107669.
Augello MA, Liu D, Deonarine LD, et al. CHD1 loss alters AR binding at Lineage-Specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis. Cancer Cell. 2019;35(4):603-617.e8.
Grbesa I, Augello MA, Liu D, et al. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell Rep. 2021;36(10):109625.
Brady NJ, Bagadion AM, Singh R, et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat Commun. 2021;12(1):3372.
Quintanal-Villalonga A, Taniguchi H, Zhan YA, et al. Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discovery. 2021;11(12):3028-3047.
Quintanal-Villalonga A, Taniguchi H, Hao Y, et al. Inhibition of XPO1 sensitizes small cell lung cancer to first- and second-line chemotherapy. Cancer Res. 2022;82(3):472-483.
Morgensztern D, Besse B, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin Cancer Res. 2019;25(23):6958-6966.
Korsen JA, Gutierrez JA, Tully KM, et al. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. Proceedings of the National Academy of Sciences. 2022;119(27):e2203820119.
Tully KM, Tendler S, Carter LM, et al. Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity. Clin Cancer Res. 2022;28(7):1391-1401.
Chen S, Huang V, Xu X, et al. Widespread and functional RNA circularization in localized prostate. Cell. 2019;176(4):831-843.
Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer. Cell. 2019;176(4):869-881.e13.
Bakht MK, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699-715.
Liu Y, Horn JL, Banda K, et al. The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Sci Transl Med. 2019;11(503):eaaw4993.
Lim Y, Arora S, Schuster SL, et al. Multiplexed functional genomic analysis of 5′ untranslated region mutations across the spectrum of prostate cancer. Nat Commun. 2021;12(1):4217.
Schuster SL, Arora S, Wladyka CL, et al. Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3′ untranslated region mutations. Cell Rep. 2023;42(8):112840.
Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398(10295):131-142.
Mao N, Zhang Z, Lee YS, et al. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nat Commun. 2021;12(1):5053.
Lorente D, Mateo J, Templeton AJ, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26(4):750-755.
Di Mitri D, Toso A, Chen JJ, et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature. 2014;515(7525):134-137.
Brina D, Ponzoni A, Troiani M, et al. The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells. Nature Cancer. 2023;4(8):1102-1121.
Su Y, Liu Y, Behrens CR, et al. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018;3(17):e121497.
Aggarwal RR, Vuky J, VanderWeele DJ, et al. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022;40(16_suppl):3001.
Wang S, Li J, Hua J, et al. Molecular imaging of prostate cancer targeting CD46 using ImmunoPET. Clin Cancer Res. 2021;27(5):1305-1315.
Bidkar AP, Wang S, Bobba KN, et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res. 2023;29(10):1916-1928.
Chen WC, Baal UH, Baal JD, et al. Efficacy and safety of stereotactic radiosurgery for brainstem metastases: a systematic review and meta-analysis. JAMA Oncol. 2021;7(7):1-9.
Sperger JM, Emamekhoo H, McKay RR, et al. Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer. J Clin Oncol. 2021;39(26):2926-2937.
Sperger JM, Helzer KT, Stahlfeld CN, et al. Expression and therapeutic targeting of TROP-2 in treatment-resistant prostate cancer. Clin Cancer Res. 2023;29(12):2324-2335.
Zhao SG, Sperger JM, Schehr JL, et al. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. J Clin Invest. 2022;132(21):e161858.
Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician's choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732.
Sia J, Hagekyriakou J, Chindris I, et al. Regulatory T cells shape the differential impact of radiation dose-fractionation schedules on host innate and adaptive antitumor immune defenses. Int J Radiat Oncol Biol Phys. 2021;111(2):502-514.
Eapen RS, Buteau JP, Jackson P, et al. Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1/2 study. European Urology. doi.org/10.1016/j.eururo.2023.08.026
Weichert JP, Clark PA, Kandela IK, et al. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014;6(240):240ra75.
Grudzinski J, et al. Theranostic combination of molecularly targeted radiotherapy and immunotherapy optimizes therapeutic response in a syngeneic murine model of Melanoma. J Nucl Med. 2018;59(suppl ment 1):178.
Patel RB, Hernandez R, Carlson P, et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13(602):eabb3631.
Jagodinsky JC, Jin WJ, Bates AM, et al. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics. 2021;11(13):6120-6137.
Thorek DLJ, Watson PA, Lee SG, et al. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. Sci Transl Med. 2016;8(367):367ra167.
McDevitt MR, Thorek DLJ, Hashimoto T, et al. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun. 2018;9(1):1629.
Bicak M, Lückerath K, Kalidindi T, et al. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proc Natl Acad Sci. 2020;117(26):15172-15181.
Morris MJ, Sartor AO, Wong JY, et al. Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer. J Clin Oncol, 2022;40(6_suppl):TPS206.
Morris MJ, O' Donoghue JA, Chetty D, et al. Pretherapeutic first-in-human targeting trial of anti-hK2 antibody h11B6: a potential molecular vector for alpha-particle radioimmunotherapy. J Clin Oncol. 2021;39(6_suppl):122.
Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun. 2014;5(1):4539.
Huntington ND, Cursons J, Rautela J. The cancer-natural killer cell immunity cycle. Nat Rev Cancer. 2020;20(8):437-454.
Dinavahi SS, Chen YC, Punnath K, et al. Targeting WEE1/AKT restores p53-Dependent natural killer-cell activation to induce immune checkpoint blockade responses in “cold” melanoma. Cancer Immunol Research. 2022;10(6):757-769.
Delconte RB, Kolesnik TB, Dagley LF, et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nature Immunol. 2016;17(7):816-824.
Morel KL, Sheahan AV, Burkhart DL, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer. 2021;2(4):444-456.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1-10.
Rousseau B, Foote MB, Maron SB, et al. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med. 2021;384(12):1168-1170.
Hurvitz SA, Caswell-Jin JL, McNamara KL, et al. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun. 2020;11(1):5824.
McNamara KL, Caswell-Jin JL, Joshi R, et al. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat Cancer. 2021;2(4):400-413.
Starrett GJ, Marcelus C, Cantalupo PG, et al. Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in Virus-Associated merkel cell carcinoma. mBio. 2017;8(1):e02079-16.
Knepper TC, Montesion M, Russell JS, et al. The genomic landscape of merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy. Clin Cancer Res. 2019;25(19):5961-5971.
Bonneville M, O'Brien RL, Born WK. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10(7):467-478.
Fichtner AS, Ravens S, Prinz I. Human γδ TCR repertoires in health and disease. Cells. 2020;9(4):800.
Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell Mol Immunol. 2020;17(9):925-939.
Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Med. 2015;21(8):938-945.
Tosolini M, Pont F, Poupot M, et al. Assessment of tumor-infiltrating TCRVγ9Vδ2 γδ lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology. 2017;6(3):e1284723.
Nussbaumer O, Koslowski M. The emerging role of γδ T cells in cancer immunotherapy. Immuno-Oncol Technol. 2019;1:3-10.
Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discovery. 2020;19(3):169-184.
Liu Z, Eltoum IEA, Guo B, Beck BH, Cloud GA, Lopez RD. Protective immunosurveillance and therapeutic antitumor activity of γδ T cells demonstrated in a mouse model of prostate cancer. J Immunol. 2008;180(9):6044-6053.
Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450-7457.
King LA, Toffoli EC, Veth M, et al. A bispecific γδ t-cell engager targeting EGFR activates a potent Vγ9Vδ2 T cell-mediated immune response against EGFR-Expressing tumors. Cancer Immunol Res. 2023;11(9):1237-1252.